Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06805825 · ClinicalTrials.gov registry record · Phase 1

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

A Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Tumors, sponsored by Novelty Nobility.

Recruiting
Registry status
Phase 1
Development phase
67
Enrollment target
5
Study locations

NCT06805825 is a Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Tumors that is actively recruiting participants, run by Novelty Nobility. The registered enrollment target is 67 participants, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (71% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06805825, a Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Tumors, is actively recruiting participants, sponsored by Novelty Nobility.

RECRUITING
Registry status
Phase 1
Development phase
67 participants
Enrollment target
5
Study locations

Study Summary

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

Conditions Studied

Small-cell Lung Cancer Neuroendocrine Tumors Clear Cell Renal Cell Carcinoma Uveal Melanoma Adenoid Cystic Carcinoma Gastrointestinal Stromal Tumors Chromophobe Renal Cell Carcinoma

Interventions

  • DRUG NN3201

Study Locations (5)

Michigan

  • University of Michigan Hospitals - Ann Arbor

Ohio

  • Case Comprehensive Cancer Center - Cleveland

Oregon

  • Oregon Health & Science University - Portland

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2025-02-03
Est. Completion 2027-12-31
Phase Phase 1

Sponsor

Novelty Nobility

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06805825

The ClinicalTrials.gov registry entry for NCT06805825 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (71% lower). The listed sponsor is Novelty Nobility, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which NN3201 is the first listed.

NCT06805825 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Michigan, Ohio, Oregon.

Frequently Asked Questions

What is clinical trial NCT06805825 about?

NCT06805825 is a clinical study titled "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit". This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

What is the current status of trial NCT06805825?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2025-02-03. Estimated completion is 2027-12-31.

What conditions does trial NCT06805825 study?

This clinical trial studies the following conditions: Small-cell Lung Cancer, Neuroendocrine Tumors, Clear Cell Renal Cell Carcinoma, Uveal Melanoma, Adenoid Cystic Carcinoma.

What interventions are being tested in trial NCT06805825?

The interventions under investigation include: NN3201 (DRUG).

Who is sponsoring clinical trial NCT06805825?

This trial is sponsored by Novelty Nobility, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06805825 being conducted?

This trial has 5 study locations across Michigan, Ohio, Oregon, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small-cell Lung Cancer

All registered trials for this condition

Neuroendocrine Tumors

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.